Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 13/20 | 0.52 |
| ▸ | MAOA | P21397 | 11/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10264374 | 0.90 | MAPT (0.53) | CA9KIF11PARP1MAOBMAOA | |
| SCHEMBL21176961 | 0.88 | MAOB (0.54) | CA9KIF11PARP1MAOBMAOA | |
| SCHEMBL30514791 | 0.88 | MAOB (0.54) | CA9KIF11PARP1MAOBMAOA | |
| SCHEMBL8203141 | 0.87 | CA9 (0.54) | CA9KIF11MAOBMAOANPC1 | |
| SCHEMBL21177055 | 0.87 | CA9 (0.48) | CA9KIF11PARP1MAOBMAOA | |
| SCHEMBL2056365 | 0.86 | KIF11 (0.66) | CA9KIF11PARP1MAOBMAOA | |
| SCHEMBL17969088 | 0.84 | CA9 (0.59) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL4509576 | 0.84 | AHR (0.56) | KIF11PARP1MAOBCRBN | |
| SCHEMBL18932523 | 0.84 | MAOB (0.53) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL18932517 | 0.83 | MAOB (0.52) | CA9MAOBMAOANPC1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210785-A1 | D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2015166398-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-11-05 | — | — | WO | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8349860-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | CA9 836/4885KIF11 3334/4885PARP1 661/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | CA9 288/4885KIF11 4747/4885PARP1 496/4885 |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | CA9 4735/4885KIF11 2709/4885PARP1 774/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | CA9 4738/4885KIF11 1587/4885PARP1 3745/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | CA9 4870/4885KIF11 1823/4885PARP1 3006/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CA9 226/4885KIF11 3567/4885PARP1 326/4885 |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CA9 224/4885KIF11 2532/4885PARP1 156/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | CA9 310/4885KIF11 2754/4885PARP1 176/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | CA9 199/4885KIF11 3909/4885PARP1 320/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CA9 226/4885KIF11 3567/4885PARP1 326/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | CA9 343/4885KIF11 2299/4885PARP1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.